December 21, 2022 10:42 AM EST

Everyone wants in on GLP-1: Pfizer doses first patient in PhII trial for diabetes and obesity drug, pays Sosei $10M

Sosei Heptares announced Wednesday morning that Pfizer dosed its first patient in a Phase II trial as part of their partnership …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Every­one wants in on GLP-1: Pfiz­er dos­es first pa­tient in PhII tri­al for di­a­betes and obe­si­ty drug, pays So­sei $10M